Royalty Pharma(RPRX) ZACKS·2025-02-11 15:31Core Insights - Royalty Pharma reported $742 million in revenue for Q4 2024, a year-over-year increase of 0.8%, with an EPS of $1.15, matching the previous year's figure [1] - The revenue exceeded the Zacks Consensus Estimate of $725.33 million by 2.30%, and the EPS surpassed the consensus estimate of $1.09 by 5.50% [1] Financial Performance Metrics - The company’s shares returned +5.8% over the past month, outperforming the Zacks S&P 500 composite's +4.2% change, and currently holds a Zacks Rank 3 (Hold) [3] - Total Portfolio Receipts from Royalty Receipts Products amounted to $729 million, exceeding the average estimate of $711.32 million, reflecting a year-over-year increase of +61.5% [4] Product-Specific Performance - Cystic fibrosis franchise generated $237 million, surpassing the average estimate of $219.16 million, with a year-over-year change of +114.4% [4] - Tysabri reported $61 million, slightly above the estimated $60.23 million, marking a +171.1% increase year-over-year [4] - Imbruvica generated $46 million, exceeding the estimate of $45.80 million, with a +180.6% year-over-year change [4] - Xtandi also reported $46 million, surpassing the average estimate of $44.22 million, reflecting a +205.6% increase year-over-year [4] - Promacta generated $44 million, exceeding the estimate of $39.82 million, with a +134.6% year-over-year change [4] - Evrysdi reported $56 million, above the estimate of $53.49 million, marking a +183.5% increase year-over-year [4] - Trodelvy generated $11 million, slightly below the estimate of $11.66 million, with a +119.5% year-over-year change [4] - Trelegy reported $74 million, exceeding the average estimate of $72.55 million, reflecting a +23% year-over-year change [4]